Poly(glycoamidoamine)s for gene delivery: Stability of polyplexes and efficacy with cardiomyoblast cells

被引:67
作者
Liu, YM [1 ]
Reineke, TM [1 ]
机构
[1] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA
关键词
D O I
10.1021/bc050275+
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Polymeric vectors have potential as nucleic acid delivery vehicles for novel gene therapy and oligonucleotide treatments for cardiovascular disease. In this report, poly(glycoamidoamine)s that contain four secondary amines and either two or four hydroxyl units in the repeat unit with D-glucarate (D4), meso-galactarate (G4), D-mannarate (M4), and L-tartarate (T4) stereochemistry have been investigated for their pDNA-binding affinity, DNase protection effect, and polyplex stability in the presence of salt and serum. Also, the luciferase gene delivery and cellular internalization of polyplexes formed with these polymers have been investigated with rat cardiomyoblast [H9c2(2-1)] cells. The results demonstrate that the number of hydroxyl groups and the stereochemistry affect the biological properties. Polymers T4 and G4 have higher pDNA binding affinity, protect pDNA from nuclease degradation, and do not release pDNA in the presence of serum. Polymers D4 and M4 bind pDNA with lower affinity, which allows for some pDNA degradation and release in the presence of serum. Although T4 forms the most stable polyplexes, vector G4 reveals the highest luciferase gene expression in serum-free media and the greatest cellular internalization of fluorescein-labeled pDNA both in serum-free and serum-supplemented media. The results of these studies indicate that the polymer-DNA binding affinity, nuclease protection capability, and polyplex stability are important parameters to facilitate effective pDNA delivery with poly(glycoamidoamine)s in cultured cardiomyoblast cells. The carbohydrate type also plays an important role to increase cellular uptake and gene expression where the polymer with the galactarate stereochemistry (in G4) is found to be the most effective vector for pDNA delivery to cardiomyoblast cells in vitro.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 35 条
[1]  
AFFKECK DG, 2001, GENE THER, V8, P349
[2]   Gene transfer and models of gene therapy for the myocardium [J].
Alexander, MY ;
Webster, KA ;
McDonald, PH ;
Prentice, HM .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1999, 26 (09) :661-668
[3]   Recent progress in polymeric gene delivery systems [J].
Anwer, K ;
Rhee, BG ;
Mendiratta, SK .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2003, 20 (04) :249-293
[4]   A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].
BOUSSIF, O ;
LEZOUALCH, F ;
ZANTA, MA ;
MERGNY, MD ;
SCHERMAN, D ;
DEMENEIX, B ;
BEHR, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301
[5]   Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery [J].
Dash, PR ;
Read, ML ;
Barrett, LB ;
Wolfert, M ;
Seymour, LW .
GENE THERAPY, 1999, 6 (04) :643-650
[6]   Novel dextran-spermine conjugates as transfecting agents: comparing water-soluble and micellar polymers [J].
Eliyahu, H ;
Makovitzki, A ;
Azzam, T ;
Zlotkin, A ;
Joseph, A ;
Gazit, D ;
Barenholz, Y ;
Domb, AJ .
GENE THERAPY, 2005, 12 (06) :494-503
[7]   Cationic lipid-mediated gene transfer: effect of serum on cellular uptake and intracellular fate of lipopolyamine/DNA complexes [J].
Escriou, V ;
Ciolina, C ;
Lacroix, F ;
Byk, G ;
Scherman, D ;
Wils, P .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1368 (02) :276-288
[8]   Potentiation of cationic liposome-mediated gene delivery by polycations [J].
Gao, X ;
Huang, L .
BIOCHEMISTRY, 1996, 35 (03) :1027-1036
[9]  
Garnett MC, 1999, CRIT REV THER DRUG, V16, P147
[10]   TRANSIENT EXPRESSION OF GENES TRANSFERRED IN-VIVO INTO HEART USING FIRST-GENERATION ADENOVIRAL VECTORS - ROLE OF THE IMMUNE-RESPONSE [J].
GILGENKRANTZ, H ;
DUBOC, D ;
JUILLARD, V ;
COUTON, D ;
PAVIRANI, A ;
GUILLET, JG ;
BRIAND, P ;
KAHN, A .
HUMAN GENE THERAPY, 1995, 6 (10) :1265-1274